DSG's eCaseLink EDC chosen for Ariosa's Non-Invasive Chromosomal Examination of Trisomy study

Ariosa Diagnostics, a molecular diagnostics company focused on prenatal testing, has chosen to use DSG's eCaseLink EDC (electronic data capture) system for the NEXT (Non-Invasive Chromosomal Examination of Trisomy) study.

“DSG is pleased to partner with Ariosa Diagnostics on their study. With the use of DSG's unique eCaseLink EDC system, we are confident in the successful outcome of the trial”

DSG's eCaseLink system captures study data electronically at the point of research, making data collection highly efficient. At any time throughout the study, clean, accurate data is available for review. DSG's eCaseLink allows Ariosa not only to collect and manage their data in real time, but also gives them the option of adding needed functionality as the study progresses.

Ariosa's NEXT study focuses on the non-invasive detection of fetal Trisomy 21 during the first trimester of pregnancy. Current methods of prenatal testing have drawbacks; invasive procedures can put both mother and fetus at risk, while conventional screening methods lack accuracy and can be difficult to implement. The NEXT study will compare the effectiveness of Ariosa's prenatal test against current standard first trimester screening for fetal Trisomy 21 detection.

"DSG is pleased to partner with Ariosa Diagnostics on their study. With the use of DSG's unique eCaseLink EDC system, we are confident in the successful outcome of the trial," says Tony Varano, CEO of DSG.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Limited impact of prenatal COVID-19 exposure on child neurodevelopmental outcomes